Food and Drug Law Journal Author Guidelines and Submission Calendar

Manuscripts and editorial correspondence should be directed to [email protected]. Authors should obtain permission to submit their manuscript for publication consideration from their employer if required.

Submission Calendar

79:4 | Deadline June 21, 2024
80:1 | Deadline September 20, 2024
80:2 | Symposium Issue
80:3 | Deadline March 21, 2025


Submissions that would be considered for publication will include an analysis of federal legislation, regulations, court decisions, and public policies affecting industries regulated by the U.S. Food and Drug Administration (FDA) and related agencies and authorities. Submissions with an international focus will be considered on a case-by-case basis, but should have substantial relevance to U.S. regulations.

Topics covered by FDLJ include the development, manufacture, marketing, and use of drugs, medical devices, biologics, food, dietary supplements, cosmetics, veterinary, tobacco, and cannabis-derived products.

The Food and Drug Law Journal encourages dialogue and analysis from diverse perspectives. In addition to feature-length articles, FDLJ welcomes the submission of student notes, excerpts from forthcoming books, Letters to the Editor, and commentary on previously published articles so long as they are relevant and timely. All pieces will go through the standard peer-review process. While word count will not hinder an article from acceptance, please note that feature articles are generally 25,000 words.


The author must prepare a short abstract, approximately 50 to 100 words, on the article. Editorial policy requires all Journal articles to use standard legal citation form as set forth in The Bluebook: A Uniform System of Citation (21st ed., The Harvard Law Review Association, Cambridge, Massachusetts).

Peer Review and Editing

Generally, all articles submitted for publication consideration are peer reviewed by members of the Journal’s Editorial Advisory Board. FDLI reserves the right to edit manuscripts accepted for publication. Members of the Food and Drug Law Journal Editorial Review Board will work with authors to provide copy editing and cite- and source-checking.

Publication Policy

Articles and any other material published in the Journal represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor-in-Chief, FDLI, or the Editorial Advisory Board Members. All submitted articles are expected to reflect the highest professional standards. Except under unusual circumstances, it is the Journal’s policy to publish only original work that has not appeared elsewhere. Manuscripts are accepted for review by the Editor-in-Chief with the understanding that the same work has not been and will not be published elsewhere; that all persons listed as authors have given their approval for the submission of the paper; and that any person cited as a source of personal communication has approved such citation.


Authors submitting a manuscript do so on the understanding that if it is accepted for publication, the copyright to the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to FDLI.

FDLI will not refuse any reasonable request by the author for permission to reproduce any of his or her contributions to the Journal. Upon publication, authors will receive a PDF version of their article suitable for posting to a website or sharing with colleagues.

Statement of Interest

Authors who have received remuneration for writing the article, or who are or have been involved as a principal or in a representative capacity with the subject matter of the article must so designate this in the affiliation footnote along with his/her current position. Full disclosure is necessary to provide reviewers and readers with useful information to assess the publication. If the paper was written to fulfill degree or school credit requirements while the author was a student, a statement to that effect must be included.

Editorial Advisory Board

The Editorial Advisory Board meets periodically in Washington, DC to discuss important current subjects within the fields of food, drug, cosmetic, medical devices, and biologics law. The Board’s function is to provide policy direction for the editorial activities of the Journal. The specific editorial statements and analyses of the Journal’s contents are not attributable to the Editorial Advisory Board, FDLI, or to any individual member or members.